IRWD vs RIGL

Ironwood Pharmaceuticals presents a high-risk profile characterized by a stable but mediocre Piotroski F-Score of 4/9 and a critical lack of equity, as evidenced by a negative Price/Book ratio of -2.26. While the stock has seen a massive 1-year price surge, this is fundamentally unsupported by a 47.3% collapse in year-over-year revenue and a significant disconnect between the current price ($3.63) and the growth-based intrinsic value ($1.05). Heavy insider selling totaling nearly $22 million further signals a lack of confidence from company leadership.

RIGL exhibits strong fundamental health with a Piotroski F-Score of 7/9 and a very conservative debt profile (Debt/Equity 0.14). The company is severely undervalued, trading at $32.43, which is significantly below both its Graham Number ($96.8) and its growth-based intrinsic value ($574.66). While technical trends and insider sentiment are currently bearish, the explosive earnings growth (1598.7% YoY) and a P/E ratio of 1.66 suggest a massive valuation gap. The transition from historical losses to consistent earnings beats indicates a successful pivot to profitability.